Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials

by Han, Kelong, Ren, Melanie, Wick, Wolfgang, Abrey, Lauren, Das, Asha, Jin, Jin, Reardon, David A.
Published 2014

Lower Exposure and Faster Clearance of Bevacizumab in Gastric Cancer and the Impact of Patient Variables: Analysis of Individual Data from AVAGAST Phase III Trial

by Han, Kelong, Jin, Jin, Maia, Mauricio, Lowe, John, Sersch, Martina A., Allison, David E.
Published 2014

Interpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastoma

by Han, Kelong, Ren, Melanie, Wick, Wolfgang, Abrey, Lauren, Das, Asha, Jin, Jin, Reardon, David A.
Published 2015

Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation

by Han, Kelong, Claret, Laurent, Sandler, Alan, Das, Asha, Jin, Jin, Bruno, Rene
Published 2016

Population pharmacokinetics of bevacizumab in cancer patients with external validation

by Han, Kelong, Peyret, Thomas, Marchand, Mathilde, Quartino, Angelica, Gosselin, Nathalie H., Girish, Sandhya, Allison, David E., Jin, Jin
Published 2016

Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation

by Han, Kelong, Peyret, Thomas, Quartino, Angelica, Gosselin, Nathalie H., Gururangan, Sridharan, Casanova, Michela, Merks, Johannes H. M., Massimino, Maura, Grill, Jacques, Daw, Najat C., Navid, Fariba, Jin, Jin, Allison, David E.
Published 2015